Biology CRO Services: Xenograft Efficacy and Safety Toxicology Studies

Altogen Labs is a preclinical contract research organization in Austin, Texas, running two kinds of study for drug development programs: efficacy studies that establish whether a compound works, and safety studies that establish whether it can be given. Both are conducted in an IACUC-regulated facility under active protocols, with GLP standards applied where a study is formally designated as GLP. One hundred percent of results and intellectual property belong to the client.

Programs typically enter at one of three points: an in vivo efficacy study in a validated xenograft model, a dose range-finding study ahead of efficacy or definitive safety work, or an IND-enabling toxicology package. Sponsors running all three with one CRO avoid the model-transfer and dose-translation gaps that appear when efficacy and safety sit at different vendors.

Efficacy studies in validated tumor models

Efficacy work is built on the company’s portfolio of 100+ in-house validated xenograft models spanning brain, breast, colon, gastric, kidney, liver, leukemia, lung, lymphoma, melanoma, ovarian, pancreatic, prostate and sarcoma indications. Each model is characterized in-house for growth kinetics and implantation parameters, so cohort sizing and study duration are set from observed behavior rather than estimated.

Cell line-derived xenograft (CDX) models are the fastest route to an interpretable in vivo result, reaching readout in five to seven weeks with cohorts large enough to support dose-response, PK/PD and tolerability readouts within a single study. Orthotopic and disseminated variants of the same lines extend that work to tissue tropism and metastatic colonization over seven to twelve weeks with imaging-based monitoring.

Patient-derived xenograft (PDX) models preserve donor histology, genomic architecture and intratumoral heterogeneity across early passages, supporting biomarker development, resistance modeling and co-clinical trial design over sixteen to thirty-two weeks. Syngeneic murine models place tumors in fully immunocompetent hosts, and humanized platforms reconstituted with human PBMC or CD34-positive cells support checkpoint inhibitors, bispecific T-cell engagers and cell therapies that conventional immunodeficient hosts cannot assess. Organoid-derived xenografts bridge ex vivo screening and in vivo validation in eight to sixteen weeks where patient material is limiting.

Efficacy endpoints

Primary endpoints are tumor volume, tumor growth inhibition, tumor growth delay and survival, with tolerability followed through body weight and protocol-defined clinical observations. Tumor volume formula, response thresholds, censoring rules and the statistical analysis plan are fixed in the protocol before the study opens, since inconsistent growth metrics are a recognized barrier to comparing results between studies.

Safety toxicology and IND-enabling studies

Dose range-finding and maximum tolerated dose studies in mouse and rat establish the dose levels every subsequent study depends on. Running that as a discrete preliminary step costs substantially less than absorbing a wrong dose inside a fully powered efficacy or definitive safety study, which in both cases has to be repeated.

From there, Altogen Labs conducts acute and repeat-dose toxicology to OECD Test Guidelines, together with safety pharmacology, immunotoxicity testing and biocompatibility testing. Study reports include methods, results, raw data and statistical analysis in a format suitable for regulatory submission.